Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Aesha Vakil
Efficacy and Toxicity of CD19-Specific Chimeric Antigen Receptor T Cells Alone or in Combination With Ibrutinib for Relapsed and/or Refractory CLL
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
Related publications
Anti-Cd19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Frontiers in Oncology
Cancer Research
Oncology
Third-Generation Anti-Cd19 Chimeric Antigen Receptor T-Cells Incorporating a TLR2 Domain for Relapsed or Refractory B-Cell Lymphoma: A Phase I Clinical Trial Protocol (ENABLE)
BMJ Open
Medicine
768. Improved Chimeric Antigen Receptor-Engineered T Cells for the Treatment of Refractory and Relapsed Leukemia
Molecular Therapy
Molecular Medicine
Molecular Biology
Pharmacology
Medicine
Genetics
Drug Discovery
Chimeric Antigen Receptor T-Cells (Car-T) for Refractory and Relapsed Burkitt's Lymphoma: Early Response in Pediatric Patients
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Retargeting CD19 Chimeric Antigen Receptor T Cells via Engineered CD19-Fusion Proteins
Cost-Effectiveness of Ibrutinib in Patients With Relapsed or Refractory (RR) Chronic Lymphocytic Leukaemia (CLL) in England
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin's Lymphoma: An Open-Label Phase 1 Trial
The Lancet
Medicine
169. Clinically Adaptable CD19-Specific Chimeric Antigen Receptor
Molecular Therapy
Molecular Medicine
Molecular Biology
Pharmacology
Medicine
Genetics
Drug Discovery
Safety and Activity of Ibrutinib in Combination With Durvalumab in Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B‐cell Lymphoma
American Journal of Hematology
Hematology
